Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor–Positive, HER2-Negative Breast Cancer

• Published in: Clinical breast cancer Vol. 16; no. 2; pp. 95 - 100.e1
• Main Authors: Iwamoto, Takayuki, Kelly, Catherine, Mizoo, Taeko, Nogami, Tomohiro, Motoki, Takayuki, Shien, Tadahiko, Taira, Naruto, Hayashi, Naoki, Niikura, Naoki, Fujiwara, Toshiyoshi, Doihara, Hiroyoshi, Matsuoka, Junji
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2016
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Chemotherapy response; Female; Follow-Up Studies; Gene Expression Profiling; Genomic marker; Grade; Hematology, Oncology and Palliative Medicine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - genetics; Neoplasm Recurrence, Local - metabolism; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; Obstetrics and Gynecology; Oligonucleotide Array Sequence Analysis; Predictive marker; Prognosis; Receptor, ErbB-2 - metabolism; Receptors, Estrogen - metabolism; Receptors, Progesterone - metabolism; Genomic marker; Chemotherapy response; Breast cancer; Grade; Predictive marker
• ISSN: 1526-8209; 1938-0666
• DOI: 10.1016/j.clbc.2015.10.004

Micro-Abstract The genomic signature of a tumor was better at identifying low-risk breast cancer cases than histologic grade alone, although testing with the genomic marker after the initial assessment of clinicopathologic markers resulted in a lower accuracy than expected. Better predictive biomarkers for neoadjuvant chemotherapy response are still needed.